Close Menu

NEW YORK – Veracyte has taken an exclusive global license to NanoString Technologies' nCounter platform for diagnostic use and has obtained the rights to NanoString's 510(k)-cleared Prosigna breast cancer prognostic test and research-use LymphMark lymphoma subtyping assay, the companies said after the close of the market Tuesday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.